Exclusive
Ipsen Secures Exclusive Rights for Sutro’s Antibody-Drug Conjugate (ADC) Portfolio in a $900 Million Agreement
Ipsen, Sutro, Antibody-Drug Conjugate (ADC), $900 million agreement, Exclusive rights
Actionable Insights Powered by AI
Ipsen, Sutro, Antibody-Drug Conjugate (ADC), $900 million agreement, Exclusive rights